Expansion
Governor Cuomo Announces Regeneron's $1.8 Billion Expansion in Westchester County
Regeneron
PR-M07-21-013-843Jul 23, 2021
COVID
Regeneron Phase III Trial Shows 81% Reduced Risk of COVID
Regeneron
PR-M04-21-014Apr 16, 2021
Collaboration
BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo Combination in Melanoma
BioNTech
PR-M08-20-NI-06Jul 31, 2020
Partnership
Regeneron Expands Partnership with RNAi Drug Developer Alnylam
Emilie Branch
Pharma's Almanac
PAO-M04-19-NI-013Apr 10, 2019
Patent
Regeneron and Sanofi Strongly Disagree with Verdict Upholding Three of Five Amgen U.S. Patent Claims Relating to PCSK9 Antibodies
Sanofi
PR-M02-19-NI-059Feb 26, 2019
Immuno-oncology
Regeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
Sanofi
PR-M01-19-NI-031Jan 10, 2019
Immuno-oncology
Sanofi and Regeneron Immuno-oncology Collaboration Ending
Nice Insight
PAO-M01-19-NI-012Jan 09, 2019
FDA Approval
FDA Approves Asthma Indication for Dupixent® (dupilumab)
Regeneron
PR-M10-18-NI-090Oct 25, 2018
Study Results
Regeneron and Teva Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip
Teva Pharmaceutical Industries
PR-M09-18-NI-059Sep 20, 2018
Regulatory
Regeneron Provides Regulatory Update on EYLEA® (aflibercept) Injection sBLA in Wet Age-Related Macular Degeneration
Regeneron
PR-M09-18-NI-016Sep 07, 2018
Collaboration
Regeneron and bluebird bio Announce Collaboration to Discover, Develop and Commercialize New Cell Therapies for Cancer
Regeneron
PR-M08-18-NI-054Aug 14, 2018